Hamostaseologie 2019; 39(S 01): S1-S92
DOI: 10.1055/s-0039-1680214
Poster
P07 Paediatric and Neonatal Thrombosis and Haemostasis and Women Issues in Thrombosis and Haemostasis
Georg Thieme Verlag KG Stuttgart · New York

Treatment of High-risk Pregnancies with Tinzaparin

H. Kiesewetter
1   Haemostaseologicum, Berlin, Germany
,
F.P. Schmidt
2   Institut für Hämostaseologie und Pharmakologie (IHP), Berlin, Germany
,
R. Becker
3   Zentrum für Pränataldiagnostik und Humangenetik, Berlin, Germany
,
M. Entezami
3   Zentrum für Pränataldiagnostik und Humangenetik, Berlin, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
13 February 2019 (online)

Also available at
 

Introduction: The effectiveness of Tinzaparin (T) in high-risk pregnancies has also been examined in combination with Acetylsalicylic Acid (ASA).

Methods: The data of 1552 pregnant women at the age between 19-53 (body height: 145-186 cm and body weight: 45-132kg) has been analyzed. 1221 have had early or late abortions or stillbirths in their prehistory. 61 of those 1221 women in combination with ASA at a secured antiphospholipid antibody syndromes (APA) (25) or Sticky Platelets (32).

In 125 cases of unsuccessful in vitro fertilization (IVF) or intracytoplasmatic sperminjections (ICSIs) in the prehistory, Tinzapirin has been injected once a day 2 days before the transfer was made. 64 with a positive pregnancie test also got ASS. 68 injected 300-400 µg rhesus antibodies before and after the transfer.

209 patients currently had notches, in detail: 25 growth retardations, 17 placental abruptions; only 14 a pre-eclampsia and 13 a HELLP-Syndrome in pre-pregnancy. 72 had an old leg vein thrombosis or an old pulmonary embolism, 18 have had a new leg vein thrombosis or a new pulmonary embolism (12 of them with an APA-Syndrome, 9 with sinus vein thrombosis, 2 with brain insults, 1 with a heart attack, 1 with an arterial occlusion in their prehistory), 9 have had a thrombophlebitis (47 with a high thrombophilic risk), 18 were smokers.

414 of those 1552 patients are taking 3.500IE, 5 4.500IE, 896 8.000IE, 158 10.000IE, 63 14.000IE and 16 18.000IE Tinzaparin. Target was the life birth rate.

Results: 1513 of the 1552 pregnant women have given birth to a healthy child, 5 of them had a pre-eclampsia and 4 had a HELLP-Syndrome. These 9 have given birth by a cesarean section. 39 patients have had an abortion so far.

120 patients who have had unsuccessful IVFs or ICSIs became pregnant at the latest after the third transfer. 85 gave birth to a healthy child. All 331 patients with notches, thrombosis, pre-eclampsia or a HELLP-Syndrome have not had any abortions. 29 patients have suffered a local allergical reaction.

Conclusions: Tinzaparin turned out to be very effective, safe and compatible and it can be safely used in pregnancies.